These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. Kleeb S; Pang L; Mayer K; Eris D; Sigl A; Preston RC; Zihlmann P; Sharpe T; Jakob RP; Abgottspon D; Hutter AS; Scharenberg M; Jiang X; Navarra G; Rabbani S; Smiesko M; Lüdin N; Bezençon J; Schwardt O; Maier T; Ernst B J Med Chem; 2015 Mar; 58(5):2221-39. PubMed ID: 25666045 [TBL] [Abstract][Full Text] [Related]
4. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660 [TBL] [Abstract][Full Text] [Related]
5. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. Klein T; Abgottspon D; Wittwer M; Rabbani S; Herold J; Jiang X; Kleeb S; Lüthi C; Scharenberg M; Bezençon J; Gubler E; Pang L; Smiesko M; Cutting B; Schwardt O; Ernst B J Med Chem; 2010 Dec; 53(24):8627-41. PubMed ID: 21105658 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Schwardt O; Rabbani S; Hartmann M; Abgottspon D; Wittwer M; Kleeb S; Zalewski A; Smieško M; Cutting B; Ernst B Bioorg Med Chem; 2011 Nov; 19(21):6454-73. PubMed ID: 21962988 [TBL] [Abstract][Full Text] [Related]
7. Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease. Sivignon A; Yan X; Alvarez Dorta D; Bonnet R; Bouckaert J; Fleury E; Bernard J; Gouin SG; Darfeuille-Michaud A; Barnich N mBio; 2015 Nov; 6(6):e01298-15. PubMed ID: 26578673 [TBL] [Abstract][Full Text] [Related]
8. The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease. Sivignon A; Bouckaert J; Bernard J; Gouin SG; Barnich N Expert Opin Ther Targets; 2017 Sep; 21(9):837-847. PubMed ID: 28762293 [TBL] [Abstract][Full Text] [Related]
9. Target Selectivity of FimH Antagonists. Scharenberg M; Schwardt O; Rabbani S; Ernst B J Med Chem; 2012 Nov; 55(22):9810-6. PubMed ID: 23088608 [TBL] [Abstract][Full Text] [Related]
10. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Spaulding CN; Klein RD; Ruer S; Kau AL; Schreiber HL; Cusumano ZT; Dodson KW; Pinkner JS; Fremont DH; Janetka JW; Remaut H; Gordon JI; Hultgren SJ Nature; 2017 Jun; 546(7659):528-532. PubMed ID: 28614296 [TBL] [Abstract][Full Text] [Related]
11. The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut. Alvarez Dorta D; Sivignon A; Chalopin T; Dumych TI; Roos G; Bilyy RO; Deniaud D; Krammer EM; de Ruyck J; Lensink MF; Bouckaert J; Barnich N; Gouin SG Chembiochem; 2016 May; 17(10):936-52. PubMed ID: 26946458 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitors. Sattigeri JA; Garg M; Bhateja P; Soni A; Rauf ARA; Gupta M; Deshmukh MS; Jain T; Alekar N; Barman TK; Jha P; Chaira T; Bambal RB; Upadhyay DJ; Nishi T Bioorg Med Chem Lett; 2018 Sep; 28(17):2993-2997. PubMed ID: 30017316 [TBL] [Abstract][Full Text] [Related]
13. Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. Jiang X; Abgottspon D; Kleeb S; Rabbani S; Scharenberg M; Wittwer M; Haug M; Schwardt O; Ernst B J Med Chem; 2012 May; 55(10):4700-13. PubMed ID: 22519985 [TBL] [Abstract][Full Text] [Related]
14. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli. Greene SE; Hibbing ME; Janetka J; Chen SL; Hultgren SJ mBio; 2015 Jun; 6(4):e00820. PubMed ID: 26126855 [TBL] [Abstract][Full Text] [Related]
15. Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. Kalas V; Hibbing ME; Maddirala AR; Chugani R; Pinkner JS; Mydock-McGrane LK; Conover MS; Janetka JW; Hultgren SJ Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2819-E2828. PubMed ID: 29507247 [TBL] [Abstract][Full Text] [Related]
16. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162 [TBL] [Abstract][Full Text] [Related]
17. Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. Mydock-McGrane L; Cusumano Z; Han Z; Binkley J; Kostakioti M; Hannan T; Pinkner JS; Klein R; Kalas V; Crowley J; Rath NP; Hultgren SJ; Janetka JW J Med Chem; 2016 Oct; 59(20):9390-9408. PubMed ID: 27689912 [TBL] [Abstract][Full Text] [Related]
18. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. Han Z; Pinkner JS; Ford B; Obermann R; Nolan W; Wildman SA; Hobbs D; Ellenberger T; Cusumano CK; Hultgren SJ; Janetka JW J Med Chem; 2010 Jun; 53(12):4779-92. PubMed ID: 20507142 [TBL] [Abstract][Full Text] [Related]